Data / Drug companies / Zydus Pharmaceuticals USA Inc.
Zydus Pharmaceuticals USA Inc.: 324 products in the FDA NDC directory, labeler code 70710
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Zydus Pharmaceuticals USA Inc. (labeler code 70710) lists 324 products in the FDA National Drug Code Directory, covering 118 finished drugs by generic name. By type: 324 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 1, 2026.
The request: Watch Zydus Pharmaceuticals USA Inc. (FDA labeler code 70710): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70710
- Products in commercial distribution
- 324
- Packages
- 578
- Finished drugs by generic name
- 118
- Prescription products
- 324
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 5, Schedule V 7
- Flagged as original packager
- 286 of 286 products that carry the flag
- Started marketing in the last 12 months
- 53
- Earliest marketing start
- February 24, 2017
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 298 | 92% |
| New drug applications (NDA) | 12 | 3.7% |
| Authorized generics (NDA) | 12 | 3.7% |
| Biologics (BLA) | 2 | 0.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 324 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 75 | 23.1% |
| Tablet | 72 | 22.2% |
| Capsule | 39 | 12% |
| Injection, solution | 32 | 9.9% |
| Injection | 26 | 8% |
| Capsule, extended release | 14 | 4.3% |
| Patch, extended release | 9 | 2.8% |
| Tablet, film coated, extended release | 8 | 2.5% |
| Kit | 7 | 2.2% |
| Injection, powder, lyophilized, for solution | 6 | 1.9% |
| Tablet, extended release | 6 | 1.9% |
| Powder, for suspension | 5 | 1.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Romidepsin | 70710-2183 | Kit | Generic drugs (ANDA) | November 1, 2026 |
| Ascorbic acid | 70710-2164 | Injection | Generic drugs (ANDA) | September 28, 2026 |
| Ascorbic acid | 70710-2163 | Injection | Generic drugs (ANDA) | September 28, 2026 |
| Ascorbic acid | 70710-2162 | Injection | Generic drugs (ANDA) | September 28, 2026 |
| Riociguat | 70710-2160 | Tablet, film coated | Generic drugs (ANDA) | September 18, 2026 |
| Riociguat | 70710-2159 | Tablet, film coated | Generic drugs (ANDA) | September 18, 2026 |
| Riociguat | 70710-2158 | Tablet, film coated | Generic drugs (ANDA) | September 18, 2026 |
| Riociguat | 70710-2157 | Tablet, film coated | Generic drugs (ANDA) | September 18, 2026 |
| Riociguat | 70710-2156 | Tablet, film coated | Generic drugs (ANDA) | September 18, 2026 |
| Indocyanine green | 70710-2018 | Kit | Generic drugs (ANDA) | August 4, 2026 |
| Fluvoxamine maleate extended-release | 70710-1848 | Capsule, extended release | Generic drugs (ANDA) | August 4, 2026 |
| Fluvoxamine maleate extended-release | 70710-1847 | Capsule, extended release | Generic drugs (ANDA) | August 4, 2026 |
| Gadobutrol | 70710-2066 | Injection | Generic drugs (ANDA) | July 14, 2026 |
| Gadobutrol | 70710-2065 | Injection | Generic drugs (ANDA) | July 14, 2026 |
| Gadobutrol | 70710-2064 | Injection | Generic drugs (ANDA) | July 14, 2026 |
| Sugammadex | 70710-1651 | Injection, solution | Generic drugs (ANDA) | July 2, 2026 |
| Sugammadex | 70710-1650 | Injection, solution | Generic drugs (ANDA) | July 2, 2026 |
| Nufymco | 70710-2173 | Injection, solution | Biologics (BLA) | June 11, 2026 |
| Nufymco | 70710-2172 | Injection, solution | Biologics (BLA) | June 11, 2026 |
| Tofacitinib | 70710-1589 | Tablet, film coated | Generic drugs (ANDA) | June 5, 2026 |
| Fluorescein | 70710-2046 | Injection | Generic drugs (ANDA) | June 2, 2026 |
| Fluorescein | 70710-2045 | Injection | Generic drugs (ANDA) | June 2, 2026 |
| Tofacitinib | 70710-1727 | Tablet, film coated, extended release | Generic drugs (ANDA) | May 20, 2026 |
| Tofacitinib | 70710-1353 | Tablet, film coated, extended release | Generic drugs (ANDA) | May 20, 2026 |
| Tofacitinib | 70710-1243 | Tablet, film coated | Generic drugs (ANDA) | May 11, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.